UTHR · UNITED THERAPEUTICS Corp
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Second-quarter revenue declined 2% year over year to $783.3 million, below expectations, while net income rose 8% to $333.0 million. The company expects a stronger second half but did not reaffirm or update its 2026 revenue-growth outlook, while potential 2027 approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH remain important growth catalysts.
- + Net income increased 8% year over year to $333.0 million.
- + Tyvaso DPI exited the quarter with record starts, referrals, commercial patients, and total patients.
- + The company expects the second half of 2026 to be stronger than the first half.
- + Potential 2027 approvals are expected for Nebulized Tyvaso in IPF and ralinepag tablets in PAH.
- − Second-quarter revenue declined 2% year over year to $783.3 million and was below expectations.
- − The company did not reaffirm or update its 2026 revenue-growth expectations.
- − The path to the previously projected $4 billion revenue run rate by the end of 2027 has narrowed.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UTHR
this stock
UNITED THERAPEUTICS Corp
|
$20.39B | +17.3% | +2.4% | 17.0 | 6.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.0% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.7% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UTHR | +21.0% | +16.1% | -0.1% | +5.4% | +17.3% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +21.4% | +16.3% | -12.5% | +5.3% | +5.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.